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TOXCATThe platelet-derived growth factor β-receptor (PDGFβR) represents an important subclass of receptor
tyrosine kinase (RTK) thought to be activated by ligand-induced dimerization. Interestingly, the receptor is
also activated by the bovine papillomavirus E5 oncoprotein, an interaction involving the transmembrane
domains of both proteins and resulting in constitutive downstream signalling. This unique mode of
activation along with emerging data for other RTKs raises important questions about the role of the PDGFβR
transmembrane domain in signalling. To address this, we have investigated the murine PDGFβR
transmembrane and juxtamembrane domains. We show for the ﬁrst time the strong oligomerization
behavior of PDGFβR transmembrane domain, forming dimers and trimers in natural membranes and
detergents; and that these self-interactions are mediated by a leucine-zipper-like motif. The juxtamembrane
regions are found to regulate these helix–helix interactions and select speciﬁcally for dimer formation. These
data provide evidence that PDGFβR is able to form ligand-independent dimers, supporting similar
observations in a number of other RTK's. A point mutant in the PDGFβR juxtamembrane domain previously
shown to cause receptor activationwas studied and yielded no change in oligomerization or folding, suggesting
(in-linewith observations of the c-Kit receptor) that itmaymoderate interactionswith other regions of PDGFβR.+44 24765 24112.
on).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Receptor tyrosine kinases (RTKs) represent a large family of
membrane proteins that play critical roles in many cellular processes.
Activation of RTKs has been widely thought to occur via ligand
binding in the extra-cellular N-terminal domain which leads to
receptor dimerization. Upon dimer formation, the intra-cellular C-
terminal kinase domains are brought into close proximity in the
proper orientation enabling autophosphorylation and leading to
activation of downstream signalling cascades (reviewed in [1]).
However, recent studies of RTKs suggest that, instead of causing
receptor dimerization, ligand binding may simply stabilize a partic-
ular dimeric conformation of the receptor, therefore shifting the
equilibrium towards an active conformation (discussed in [2]). In a
number of cases, RTKs have been shown to exist as ligand-
independent inactive dimers or tetramers, which undergo a confor-
mational change upon ligand binding [3,4]. In either case, RTK
activation involves the transmission of information from the extra-
cellular ligand binding domain to the intra-cellular signalling domain.
This suggests a possible role for the transmembrane (TM) domain in
the formation of active receptor complexes and indeed this has been
demonstrated in an increasing number of receptor subclasses [2,5,6].Further investigations involving the study of this key region of RTKs
will undoubtedly increase our understanding of these important
receptors.
The platelet-derived growth factor β receptor (PDGFβR) is a type
III RTK with functions in cell growth, shape, and chemotaxis [7,8]. A
fundamental role for the TM domain of PDGFβR in receptor activation
is demonstrated by its productive interaction with E5, a small viral
oncoprotein from bovine papillomavirus [9–11]. E5 is able to bind and
activate the receptor without any involvement from the ligand
binding region [12–15] and residues within the TM domains of
both proteins have been shown to be critical for activation [16–20]. It
is thought that an E5 homodimer is able to recruit two PDGFβR
monomers resulting in an E5-stabilized dimeric receptor [21].
However, the mechanistic details of this process are unknown.
Using the rationale above, E5 binding could also trigger a conforma-
tional change in a pre-formed PDGFβR dimer, preferentially stabiliz-
ing the active state. At present there is no evidence for the formation
of inactive PDGFβR dimers.
Previous studies of PDGFβR have centered on the soluble regions
of the protein. The structure of the extra-cellular domain has been
well studied [22,23]; and a crystal structure of the closely-related
stem cell factor (c-Kit) receptor N-terminal domain is also available
[24]. The juxtamembrane (JM) region has been shown to have an
important function in both PDGFβR and c-Kit, with mutations in the
former leading to constitutive receptor activation [25,26] and
mutations in the latter leading to a number of tumours [27,28].
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primarily on the interaction with E5, with few studies exploring the
homo-oligomerization behavior of the TM domain in detail [12,13].
Understanding the role of the TM domain will have signiﬁcant
implications in uncovering the molecular mechanism of receptor
activation both for PDGFβR and RTK's in general.
Here we address these issues though a detailed investigation of
the murine PDGFβR TM and JM domains. We detect strong self-
association of the TM domain, which appears to form both dimers and
trimers in vitro, and describe a possible role for a leucine-zipper-like
motif in this self-association.We show that the strong oligomerization
of the TM domain is moderated by the JM regions of the protein. A
point mutant in the PDGFβR JM domain (V536A) previously shown
to cause receptor activation [25] was also studied and yielded no
changes in either receptor oligomerization or protein fold, and may
lead to receptor activation via changes in interactions with other
proteins or with other regions of the PDGFβ receptor.
2. Materials and methods
2.1. TOXCAT in vivo oligomerization assay
To probe the propensity of the TM domain of PDGFβR to
oligomerise in vivo, the TOXCAT assay was used as described
previously [29,30]. Brieﬂy, the DNA sequence corresponding to
residues K499–W524 of the mature murine PDGFβR was cloned in
to the pccKAN vector between the dimerization-dependent DNA-
binding domain of ToxR, and maltose binding protein (MBP), and
expressed in Escherichia coli cells. TM domain-driven oligomerization
of the fusion protein leads to ToxRmediated activation of the reporter
gene chloramphenicol acetyltransferase (CAT). The level of CAT
expression is proportional to the strength of TM self-association,
with data being normalized to the strongly dimeric TM domain from
glycophorin A (GpA). Prior to carrying out the assay, correct mem-
brane insertion was conﬁrmed via protease sensitivity in a sphero-
plast assay [30] and comparable expression levels conﬁrmed by
immunoblotting using an antibody against MBP. The FAST CAT kit
(Invitrogen) was used to perform the CAT assays according to the
manufacturer's instructions. Mutagenesis was performed by Quik-
change mutagenesis (Stratagene) according to manufacturer's
instructions.
The resulting CAT activities were normalized for total fusion
protein expression using the ImageJ program [31] to quantitatively
analyze expression levels (i.e. intensities of bands) in anti-MPB
western blots of each chimera. Statistical evaluation of all TOXCAT
data from wt PDGFR and the various mutants was then carried out
using a Student's t-test with four degrees of freedom (DOF=4) and a
probability (p) of 0.05 (95% conﬁdence interval) to establish whether
the effect of a given mutation was signiﬁcant within the error.
2.2. Peptide synthesis and puriﬁcation
A peptide corresponding to the TM domain of PDGFβR was syn-
thesized at the Keck Facility (Yale University), using F-moc chemistry.
The full sequence of the peptide was Ac-KFKVVVISAILALVVLTVISLII-
LIMLWQKK-CONH2 containing residues F498 to K527 of the mature
protein with the addition of one non-native lysine residue at the N-
terminus to aid solubility and end caps on the N- and C-termini.
The crude peptide was puriﬁed by reverse-phase HPLC on a semi-
preparative C4 column (Phenomenex) using a linear gradient of
acetonitrile containing 0.1% triﬂuoroacetic acid (TFA) for the mobile
phase. Pure fractions (95%) were conﬁrmed by electrospray mass
spectrometry, pooled and lyophilised (mass predicted=3535 Da;
mass observed=3536. Peptide concentrations were calculated from
the absorbance at 280 nm using amolar extinction coefﬁcient (ε280) of
5500 mol−1 cm−1.2.3. Analytical ultracentrifugation
The PDGFβR TM domain peptide was prepared in 50 mM Tris
buffer (pH 7.5), containing 15 mM dodecylphosphocholine (DPC)
(Avanti Polar Lipids, Alabaster AL, USA), 100 mM NaCl, and 52.5% D2O
(Cambridge Isotope Laboratories, Andover MA, USA) to match the
buoyant density of the detergent. Sedimentation equilibrium and
sedimentation velocity measurements were carried out and analyzed
as described previously [32]. Brieﬂy, sedimentation velocity data were
recorded at a speed of 40,000 RPM and a temperature of 20 °C using
a double-channel centerpiece, interference optics, and peptide
concentrations of 96 µM and 48 µM. The resulting data proﬁles were
ﬁt using the program Sedﬁt [33] to generate a continuous sedimen-
tation coefﬁcient distribution, which was subsequently converted to a
molecular mass distribution. Equilibrium data were recorded at 20 °C
using absorbance optics set to 280 nm, a six-channel centerpiece, and
peptide concentrations of 96 µM, 64 µM and 32 µM. Measurements
were taken at three speeds (37,000, 40,000 and 43,000 RPM). The
PDGFβR TM peptide monomeric molecular mass in 52.5% D2O was
determined to be 3.56 kDa (corrected for H–D exchange) using the
program SEDNTERP (available at http://www.rasmb.bbri.org/).
Global ﬁtting of all nine data sets was carried out using a non-linear
least-squares curve ﬁtting algorithm in the program Win-NONLIN
[34].
2.4. SDS-polyacrylamide gel electrophoresis (PAGE)
The PDGFβR TM peptide was prepared for electrophoresis by
dissolving the required amount of peptide in 50 mM sodium phos-
phate buffer (pH 7.5) containing 10 mM sodium dodecyl sulphate
(SDS), and 100 mMNaCl. Samples were applied to a 12% NuPAGE Bis–
tris gel (Invitrogen) according to manufacturers' guidelines. Peptide
visualization was achieved by staining with Coomassie-R250.
2.5. Computational searches using CHI
Structural calculations were carried out using the CNS searching of
helix interactions (CHI) method [35], on an 8 node dual 2.66 GHz
Xenon processor Linux cluster (Streamline computing, Warwick, UK)
as described previously [29]. Both dimer and trimer models were
calculated containing residues K499–W524 from the mature PDGFβR
sequence. Starting geometries incorporated both left- and right-
handed crossing angles of 25°; with a distance of 10.4 Å (dimer) and
11 Å (trimer) between the helices. Full searches of the dimer were
carried out by rotating each helix around its central axis through 360°
in 45° increments, while symmetrical searches of the trimer were
conducted by rotation of the helices in 10° increments, followed by
simulated annealing and energy minimization. Clusters of 10 or more
structures with a backbone RMSD of ≤1 Å were created and an
average structure calculated.
2.6. Cloning and expression of truncated PDGFβR and V536A mutant
Expression of the truncated PDGFβR, containing the TM domain
plus 40 residues from both the C- and N-terminal JM regions, was
performed as follows. The following PCR primers were used to amplify
DNA corresponding to residues V460–P564 of mature PDGFβR (kindly
provided by Prof. D. DiMaio, Yale University), incorporating BamH1
and Xho1 restriction sites at the 5′ and 3′ ends, respectively
(underlined): forward GCATGCGATCCGTGAGCACACTGCGCCTGCGC-
CACG; reverse GCATGCCTCGAGTGGCAGCTCCCAGGTGGAGTCGTAA.
This was subsequently ligated into the multiple cloning site of the
pET30a vector (Novagen), resulting in a construct containing a
hexahistidine (His) tag at both the N- and C- termini and a linker
region between the N-terminal His tag and the start of PDGFβR. The
V536A mutation was constructed using the Quikchange site-directed
Fig. 1. Oligomerization of PDGFβR TM domain in E. coli membranes. (A) Sequence of
PDGFβR transmembrane domain analyzed using the TOXCAT assay (residues K499–
W524). (B) Results of TOXCAT assay showing CAT activities obtained for the positive
and negative controls, namely the TM domain of glycophorin A (GpA) and its
dimerization-defective mutant G83I, along with the PDGFβR TM domain. CAT activities
are means (after normalization to fusion protein concentration, and then to the value
for GpA) of three or more independent measurements +/− the standard error of the
mean (SE). Western blots against maltose binding protein (MBP) are shown below the
TOXCAT data to conﬁrm expression levels of each fusion protein.
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Protein expression was carried out in the BL21 strain of E. coli, using
1 mM IPTG to induce expression from the T7 promoter once the
culture reached mid-exponential phase. The cells were cultured for a
further 4 h before being harvested by centrifugation at 3000×g. The
resulting pellets were stored at −80 °C until required.
2.7. Puriﬁcation of truncated PDGFβR protein
The truncated PDGFβR protein was directed to inclusion bodies.
To isolate the protein, cell pellets were ﬁrst resuspended in 5 ml
Tris–acetate (pH 8.2), followed by addition of protease inhibitors
(inhibitor cocktail set VII, Novagen). Lysozyme and DNase were
added to ﬁnal concentrations of 0.2 mg/ml and 10 µg/ml, respec-
tively, and incubated on ice for 5 min, followed by 3×30 s sonication
steps using a probe tip sonicator. Inclusion bodies were isolated by
centrifugation for 90 min at 50,000×g in a Sorvall RC 6 Plus cen-
trifuge. The resulting pellet was solubilized using 6 M guanidine
hydrochloride in buffer containing 100 mM sodium phosphate and
10 mM Tris pH 8, for 16 h at 4 °C with gentle rotation. Insoluble
material was removed by centrifugation at 50,000×g for 15 min. The
supernatant was incubated with 1 ml of His-bind resin (Novagen)
for 4 h at 4 °C. This mixture was subsequently decanted into a plastic
disposable column, and the liquid drained off. The resin containing
bound proteinwas then washedwith 4 column volumes (CVs) of 8 M
Urea in 100 mM sodium phosphate buffer (pH 8). Protein refolding
was achieved by washing the resin with 20 CVs detergent buffer
containing 0.1% n-dodecyl-β-D-maltoside (DDM) (Calbiochem),
50 mM sodium phosphate (pH 8), 300 mM sodium chloride, and
5% glycerol. Any non-speciﬁcally binding proteins were removed
by washing the resin in detergent buffer containing increasing
amounts of imidazole. Bound protein was eluted using 6×1/2 CV of
detergent buffer containing 300 mM imidazole. Desalting and
removal of imidazole was achieved using a PD10 column (Amer-
sham) according to manufacturer's guidelines. Protein concentra-
tions were estimated from the absorbance at 280 nm using a molar
extinction coefﬁcient (ε280) of 22,460 mol−1 cm−1.
2.8. Chemical crosslinking
Crosslinking reactions were carried out by addition of the bis
(sulfosuccinimidyl) suberate (BS3) (Pierce) crosslinker to puriﬁed
protein in 0.1% DDM. The reaction was allowed to proceed for 30 min
followed by subsequent addition of quencher (20 mM Tris). Cross-
linked and uncrosslinked protein samples were applied to a 12%
NuPAGE Bis–tris gel (Invitrogen) according to manufacturer's guide-
lines. Protein visualization was achieved by immunoblotting using
antibodies against the C-terminal His tag (Invitrogen). The ImageJ
program [31] was then used to measure the relative intensities of the
bands in high-resolution images of the resulting Western blots, and
these intensities were used to calculate the % dimer (%d) according to
the equation:
%d =
Id
Im + Id
 
× 100
where Id was the intensity of the dimer band and Im was the intensity
of the monomer band.
2.9. Circular dichroism (CD)
CD measurements were carried out on a Jasco J715 or J815
spectropolarimeter, using a 1 mm path-length quartz cuvette (Starna,
Optiglass Ltd). Spectra were recorded from 260 nm to 195 nm with a
2 nm bandwidth, 0.2 nm data pitch, 100 nm min−1 scanning speed,
and a 1 s response time. For temperature controlled experiments, aPeltier thermally-controlled cuvette holder was used. Data shown
were averaged from four individual spectra and measurement of the
buffer without peptide was subtracted to obtain the ﬁnal spectrum.
Puriﬁed protein samples were measured in buffer containing 0.1%
DDM, 50 mM sodium phosphate (pH 8), 100 mM sodium chloride,
and 5% glycerol. The ﬁnal protein concentration was 24 µM. Analysis
of secondary structure content was performed using CDSSTR software
[36] and the prediction program PROFsec on the PredictProtein server
[37].3. Results
3.1. Oligomerization of the TM domain of murine PDGFβR in vivo
The TM domains of a number of RTKs have been shown to play a
central role in receptor activation and signal transduction (reviewed
in [2]). However, there are currently no data for the TM domain of
PDGFβR, or any other type III RTK. The ability of the PDGFβR TM
domain to oligomerize in natural membranes (speciﬁcally, the inner
membrane of E. coli) was determined here using the TOXCAT assay
[30]. This assay has been used to deﬁne the oligomerization behavior
of a number of TM domains including those from other RTKs
[6,29,38,39]. The amino acid sequence of the predicted TM domain
of the murine PDGFβ receptor (Fig. 1A) was expressed as a fusion
protein containing an N-terminal ToxR DNA-binding domain and
maltose binding protein at the C-terminus. In the TOXCAT assay,
oligomerization of the TM domain leads to ToxR dimerization, and
expression of the reporter protein chloramphenicol acetyl transferase
(CAT). Reporter activity is compared to that of the strongly dimerizing
TM domain from glycophorin A (GpA) [40] and a dimerization-
defective mutant of GpA (G83I). The results are presented in Fig. 1B,
after normalization of the data for expression level (see Materials and
methods), where high CAT activity was observed for the PDGFβR
TM domain. The data for the wt PDGFβR TM domain and that of
Fig. 2. TOXCAT analyses of PDGFβR TM domain mutants. (A) Amino acid sequences of
the wild-type (WT) PDGFβR TM domain, point mutants K499A and T513A, and the
poly-alanine mutants. (B) CAT activities obtained from the TOXCAT assay using these
sequences. (C) Amino acid sequences of wt PDGFβR TM domain and the various
tryptophan point mutants. (D) Resulting CAT activities obtained from these sequences.
In both cases, CAT activities are means (after normalization to fusion protein con-
centration, and then to the value for wt PDGFβR) of three or more independent
measurements +/− the standard error of the mean (SE). Western blots against
maltose binding protein (MBP) are shown below the TOXCAT data to conﬁrm
expression levels of each fusion protein.
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see Materials and methods). This analysis indicated that there was
no signiﬁcant difference between the signals of PDGFβR and GpA,
demonstrating the intrinsic ability of the PDGFβR TM domain to
mediate oligomerization in a natural membrane environment.
3.2. Mutagenic strategies to locate regions of the TM domain that
mediate oligomerization
To investigate which residues or sequence motifs are involved in
oligomerization of the TM domain, a site-directed mutagenesis
approach was used. Firstly, since TM domain interaction with the
BPV E5 protein leads to receptor activation, we proposed that residues
known to be involved in the interaction with E5 would not be
involved in homo-oligomerization of PDGFβR. Speciﬁcally, K499 in
the PDGFβR TM domain is predicted to interact with D33 of E5 while
T513 is expected to form a hydrogen bond to Q17 of E5 [19]. In our
experiments, both of these residues were replaced with alanine as it is
neither charged nor capable of hydrogen bond formation (Fig. 2A);
the resulting CAT activities are shown in Fig. 2B. Comparison of
the data obtained for the wt PDGFβR TM domain with these two
mutants using a Student's t-test (DOF=4; p=0.05) indicates that the
differences in the data resulting from either mutation are not
statistically signiﬁcant, and suggests that neither of these mutations
signiﬁcantly altered the oligomerization behavior of the TM domain.
Thus we can conclude that the E5 binding interface is not involved in
PDGFβR homo-oligomerization. This is not surprising given that
residues known to interact with E5 are likely to be accessible and not
participating in other interactions.
Apart from residues that contribute to productive interaction with
E5, there is very little known about the role of individual residues in
the PDGFβR TM domain. To address this we initially chose to apply a
coarse systematic approach to broadly locate regions of the TM
domain which affect oligomerization. This was performed by the
successive replacement of groups of ﬁve consecutive residues with
ﬁve alanine residues along the length of the TM domain to generate
ﬁve poly-alanine mutants (Ala 1–Ala 5, moving from the N- to the C-
terminus; Fig. 2A). Analyses of the data shown in Fig. 2B using a
Student's t-test (DOF=4; p=0.05) indicate that, with the exception
of the Ala 3 mutant at the center of the TM domain, all of the
remaining four poly-alanine mutations signiﬁcantly alter the CAT
activity as compared to wt PDGFβR. The mutants at either end of the
TM domain (Ala 1 and Ala 5) greatly reduce homo-oligomerization,
suggesting that these residues affect packing interactions between the
helices. Only one poly-alanine mutant, Ala 2, had a positive effect on
TM domain self-association. Closer examination of the sequence
covered by Ala 2 reveals a small–XXX–small motif (S504–XXX–
A508); this type of motif is closely related to the GXXXGmotif [41,42]
and is believed to be involved in contributing to helix–helix
interactions in other membrane proteins [6,43]. The SXXXA motif is
also well conserved in other RTKs [44]. Here, however, mutation of
A508 with either leucine (data not shown) or tryptophan (Fig. 2C–D)
resulted in no signiﬁcant change (as evaluated by Student's t-test) in
the observed CAT activity as compared to wild-type. It therefore
seems unlikely that this motif is signiﬁcantly contributing to
oligomerization; however given that the results from alanine
scanning mutagenesis show a marked increase in oligomerization
propensity in this region, small residues are clearly favourable at these
positions.
To look for a possible interaction interface, we undertook trypto-
phan scanning mutagenesis in the central region of the TM domain,
covering each face of the helix from A508 to T513. This type of
mutagenesis has been applied successfully in previous studies where
placing a tryptophan residue at the interface was presumed to disrupt
oligomerization [45,46], however the converse has also been reported
[47]. Therefore, for the Trp point mutants, we simply looked forchanges (positive or negative) in CAT activity. The results presented in
Fig. 2D demonstrate a signiﬁcant change (as evaluated by Student's t-
test) in CAT activity upon mutation of two positions: L509, and V511.
For both mutants, an apparent increase in oligomerization is
observed. Plotting these residues on a helical wheel for a left-handed
coiled-coil (as shown in Fig. 3A and previously in [19]) places them on
Fig. 3. Helical wheel and SDS-PAGE analyses of the PDGFβR TM domain. (A) The
PDGFβR TM domain sequence plotted on a helical wheel plot for a left-handed coiled-
coil. The positions shown to produce large changes in the Trp scan are shown in bold.
(B) (left panel) SDS-PAGE analyses of a synthetic peptide corresponding to the TM
domain of PDGFβR. Puriﬁed peptide was dissolved in buffer containing 10 mM SDS to
give ﬁnal peptide concentrations between 15 and 150 µM. Peptide visualization was
achieved by staining with Coomassie-R250. Molecular weight markers are shown in the
left-hand lane. Oligomeric states are indicated on the right (m=monomer, d=dimer,
t= trimer, dd=dimer of dimers or tetramer). (right panel) Similar SDS-PAGE analysis
of a peptide containing the TM domain of the E5 protein. Comparison of the migration
pattern of the E5 TM peptide, which is approximately the same mass and known to
form a strong dimer [32]), to that of the PDGFβR TM peptide suggests that the PDGFβR
band labelled d is most likely a dimer.
Fig. 4. Sedimentation velocity analysis of the PDGFβR TM domain. The PDGFβR peptide
was prepared in 15 mM DPC as described in Materials and methods and sedimentation
velocity data were collected using a double-channel centerpiece and a speed of
40K RPM. Data obtained at two different peptide concentrations (96 and 48 µM) were
analyzed using the program Sedﬁt [33]. The molar mass distribution from the 96 µM
(solid line) and 48 µM (dotted line) samples are shown, and the peak maxima
correspond to masses of 11.7 and 9.5 kDa, respectively. The ﬁt residuals at each con-
centration are shown in the upper plots.
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from this data alone what effects the Trp residues have on structure,
the data suggest at a minimum that more than one interface may be
involved in the interaction and/or more than one oligomeric state
may be present in the membrane.
3.3. PDGFβR TM domain peptide can form dimeric and trimeric
complexes in vitro
Since the TOXCAT assay cannot report on the order of the
oligomers formed in the membrane, the oligomeric state of the
PDGFβR TM domain was studied using a synthetic peptide containing
residues F498 to K527 of the full-length protein (see Materials and
methods for sequence). The puriﬁed peptide was analyzed by SDS-
PAGE and visualized by staining with Coomassie R-250. Fig. 3B shows
themigration pattern produced by four different concentrations of the
peptide. Four distinct bands are present on the gel which we initially
assumed represent the monomer, dimer, trimer and tetramer (or
dimer of dimers) states. It is clear from this result that the TM domain
is forming SDS-stable homo-oligomeric complexes, in good agree-ment with our observations in natural membranes using the TOXCAT
assay (see above). SDS-stable TM domain oligomers are not un-
common in the literature [32,40], although recent reports urge
caution when interpreting results from SDS-PAGE because, in some
cases, slower migration is caused by differential detergent binding
rather than oligomerization [48,49]. Here a monomer band is clearly
present at the correct molecular weight (3.5 kDa, labelled m in
Fig. 3B) and therefore it can be concluded that the other three bands
represent higher-order oligomeric species. However, the oligomer
bands are migrating slightly slower than would be expected from the
calculated molecular weight of the peptide dimer (7 kDa), trimer
(10.6 kDa), and tetramer (14.1 kDa). The position of the dimer band
(labelled d in Fig. 3B) is very similar to that from another strongly
dimeric TM domain peptide of approximately the same mass (the TM
domain of the E5 protein, see Fig. 3B, right panel [32]), indicating that
this band is most likely a PDGFβR dimer. Themost intense band on the
gel is directly above the dimer band, and we have provisionally
assigned that to the trimeric species. Finally, the highest band on the
gel (and the weakest of the oligomer bands) has been assigned to
tetramer (or a dimer of dimers). Thus, our analyses suggest that the
PDGFβR TM domain migrates predominantly as dimers and trimers
on SDS-PAGE gels, with some tetramer formation at the highest
peptide concentrations.
In order to determine more accurately the oligomeric state(s)
adopted by the PDGFβR TM domain peptide, we carried out analytical
ultracentrifugation (AUC) studies using the less-denaturing detergent
dodecyl phosphocholine (DPC). AUC is a powerful technique well-
suited to investigation of membrane protein complexes, as compar-
ison to standards is not required and thermodynamic parameters can
be obtained. Firstly, sedimentation velocity experiments were carried
out at two different peptide concentrations (both solubilized in
Fig. 5. Sedimentation equilibrium analysis of the PDGFβR TM domain. Global analysis of
three concentrations of the PDGFβR peptide ranging from 96 to 32 µM, at three separate
speeds (37K, 40K, and 43K RPM), is shown in the lower panel. In all samples, peptide
was dissolved in 15 mM DPC detergent. Filled circles represent experimental data, and
solid curves display the best ﬁt resulting from the global analysis of all nine datasets, in
this case a monomer–dimer–trimer model. The residuals of the ﬁtting process at each
speed are shown in the upper panels.
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root mean squared deviations (RMSDs) for the ﬁtting were 1.3×10−2
and 1.2×10−2 for the 94 µM and 48 µM samples, respectively. In the
sample containing 94 µM peptide, themass distribution proﬁle gives a
peak molecular weight of 11.7 kDa, which is just above the calculated
mass of the trimeric species (10.7 kDa, accounting for H/D exchange
in 52.5% D2O). Given the relative broadness of the peak, a contribution
from other oligomeric complexes is very likely; the small difference in
size between dimer and trimer for example would be very difﬁcult to
resolve. Interestingly, the peak position is slightly shifted towards
lower molecular weight species in the lower concentration sample
(48 µM) yielding a peak molecular weight of 9.5 kDa, lying between
the dimer and trimer molecular weights.
To complement these data, and to obtain thermodynamic infor-
mation about the interaction, sedimentation equilibrium experiments
were carried out. Global analyses were performed on data sets
obtained for three peptide concentrations (from 32 to 96 µM) at three
different speeds (37,000, 40,000 and 43,000 RPM), using a non-linear
least-squares ﬁtting procedure. Initial ﬁtting to an ideal single species
model yielded a mass value closely corresponding to that of the
trimer, which is in good agreement with the velocity and electropho-
resis data and indicates that the majority of the peptide is in a trimeric
state. Fitting to various simple monomer/n-mer equilibria suggested
that a monomer/trimer model best described the data (as judged by
the randomness of the ﬁt residuals and theminimization of the square
root of variance (SRV), see Table 1). Interestingly, the addition of a
dimeric species into the monomer/trimer model further improved
the ﬁt (Table 1). To obtain realistic values for the association constant,
a non-ideality term (in best ﬁt, B=−0.0364; see Fig. 5) was also
included in the ﬁtting process. Non-ideal behavior in these types
of associating systems has been observed and discussed previously
[32]. The resulting global ﬁt of the data to a monomer/dimer/trimer
equilibrium, as well as the ﬁt residuals, are shown in Fig. 5. Analysis of
the ﬁt yielded apparent monomer/dimer and monomer/trimer
dissociation constants (Kd,app) of 500 µM and 24 nM, respectively.
These values were converted to apparent free energies of dissociation
ΔGapp=4.4 kcal mol−1 for the dimer and 10.2 kcal mol−1 for the
trimer at 20 °C. To facilitate comparison of this value to other
published data and take into account detergent concentration, ΔGapp
was then converted to a mole fraction standard state free energy of
dissociation as described previously [32,50]. This conversion resulted
in free energies of dissociation of 2.0 kcal mol−1 for the PDGFβR TM
dimer and 7.8 kcal mol−1 for the PDGFβR TM trimer (as compared to
7.0 kcal mol−1 for the GpA TM dimer [50] and 5.0 kcal mol−1 for the
E5 TM dimer [32]).
These data demonstrate that in isolation the PDGFβR TM domain
forms a very strong trimer and a more weakly-associating dimer.
Interestingly, although there are no previous data to suggest that full-
length PDGFβR can form a trimer in vivo, the TM domains of the ErbB
family of RTKs have also been observed to form trimers in AUC
experiments [51].Table 1
Non-linear least-squares ﬁtting statisticsa for sedimentation equilibrium data and
resulting dissociation constantsb for PDGFβR TM domain.
Fit Variance SRS SRV DOF Kd (M) dimer Kd (M) trimer
M 2.94×10−4 0.17 1.72×10−2 561 – –
M/D 1.15×10−2 6.45 1.07×10−1 561 – –
M/Tr 7.53×10−5 0.042 8.67×10−3 561 – 2.68×10−8
M/Tet 9.02×10−5 0.051 9.50×10−3 561 – –
M/D/Tr 7.39×10−5 0.042 8.60×10−3 561 5.0×10−4 2.39×10−8
a Statistics are given for ﬁts to monomer (M), monomer–dimer (M/D), monomer–
trimer (M/Tr), monomer–tetramer (M/Tet) and monomer–dimer–trimer (M/D/Tr)
equilibria. Variance of ﬁt, sum of residuals squared (SRS), square root of variance (SRV),
and the number of degrees of freedom in the ﬁt (DOF) are shown.
b Also shown are the apparent dissociation constants (Kd) as calculated from the ﬁts
for both dimer and trimer.3.4. Structural models and mutagenesis of PDGFβR TM domain indicate a
leucine-zipper-like motif stabilizes oligomer formation
In order to identify helix–helix interactions capable of stabilizing
dimer and trimer formation, molecular modelling was carried out
using the program CHI (see Materials and methods for details).
Symmetrical left-handed coiled-coil geometries were selected based
on previous studies of the PDGFβR TM domain by Petti et al. [19].
Representative structures emerged through multiple searches of both
oligomeric states. The residues lying at the protein–protein interface
(which were very similar in all structures obtained) are highlighted in
both the TM domain sequence and the structural models of the dimer
(Fig. 6 A–B) and the trimer (Fig. 6 C–D). CHI was also used to predict
the energetic contribution of each amino acid to helix–helix
interactions, and the resulting plots of the interaction energies for
the dimer and trimermodels are shown in Fig. 6E. From these data it is
interesting (but not surprising) to note that the interaction ‘peaks’ are
broader in some cases for the trimer, with two consecutive residues
yielding signiﬁcant interactions energies and indicating that more
than one interaction interface is present.
Aside from this difference, the CHI-predicted interfaces for both
the dimer and the trimer are very similar, particularly towards the C-
terminus of the TM domain, and suggest that the TM domain self-
associates via knobs-into-holes (or leucine-zipper) packing [52,53].
In a leucine-zipper, the interacting amino acids form a repeating
motif (a heptad repeat) consisting of seven residues (a–g). Non-
611J. Oates et al. / Biochimica et Biophysica Acta 1798 (2010) 605–615polar/branched residues such as Leu and Ile usually occupy positions
a and d of the heptad repeat, and these positions have been labelled
beneath the PDGFβR TM domain sequence in Fig. 6A and C. For both
oligomers in Fig. 6E, it can be seen that residues A505, L509, L512,
S516, I519, and L523 occupy the a and d sites. Apart from A505 and
S516, these residues are exactly in keepingwith what is expected for a
heptad repeat in an α-helical coiled-coil. In order to experimentally
test whether or not these residues pack in a natural membrane
bilayer, we created three mutants along the predicted leucine-zipper
interface replacing small residues with Leu (A505L, S516L) or large
residues with Ala (I519A) as shown in Fig. 7A. We then tested the
effects of each point mutation using the TOXCAT assay (Fig. 7B).Fig. 7. Mutation of the proposed PDGFβR TM domain leucine-zipper-like interface.
(A) Amino acid sequences of the wild-type (wt) PDGFβR TM domain, and point
mutants of residues thought to lie on the leucine-zipper-like interface (depicted in
Fig. 6). (B) CAT activities obtained from the TOXCAT assay using these sequences. CAT
activities are means (after normalization to fusion protein concentration, and then to
the value for wt PDGFβR) of three or more independent measurements +/− the
standard error of the mean (SE). Western blots against maltose binding protein (MBP)
are shown below the TOXCAT data to conﬁrm expression levels of each fusion protein.Although mutation of A505L had no signiﬁcant effect on helix–helix
association in TOXCAT, analysis of the data using a Student's t-test
(DOF=4; p=0.05; see Materials and methods) indicates that
replacing S516 with Leu signiﬁcantly increases self-association. This
result supports our theory that the TM domain self-associates via a
leucine-zipper motif, as populating the a and d positions with Leu and
Ile should strengthen this interaction. Conversely, we also tested the
effect of removing an interfacial Ile residue (I519, predicted to lie at
position d in the heptad repeat) with an Ala residue in an attempt to
destabilize helix–helix interactions. As shown in Fig. 7B, this mutation
does indeed produce a statistically signiﬁcantly decrease in self-
association (as indicated by t-test), further strengthening the
argument that the a and d positions show a clear preference for
branched amino acids as predicted for a leucine-zipper.
Finally, shown in Fig. 6B and 6D are the relative positions of the
K499 and T513 residues in the dimer and the trimer models. In theFig. 6. Computational models of PDGFβR TM domain dimers and trimers. Molecular
models were created using the program CHI as described in Materials and methods.
(A) The sequence of the murine PDGFβR TM domain, with residues falling on the dimer
interface shown in bold. Beneath the sequence is the general notation for a heptad
repeat motif, identifying the position of the interfacial residues within the motif. In this
arrangement, all of the interfacial residues are located at the critical a and d positions
(shown in bold). (B) Front and side views of a representative left-handed dimer model,
with individual helices represented as ribbons and residues lining the interface
depicted as space-ﬁlling spheres. Thesemodels highlight the close packing of interfacial
residues and the orientation of K499 and T513 (shown in stick representation) away
from the dimer interface. (C) Positions of the residues falling on the PDGFβR TMdomain
trimer interface (shown in bold), and their location at positions a and d of the heptad
repeat motif. (D) Side and top-views of a representative left-handed trimer model,
again illustrating the packing of interfacial residues and accessibility of K499 and T513.
(E) Plot of the predicted interaction energy contribution from each amino acid along
the TM domain sequence (K499–W524) in the dimer (solid line) and the trimer
(dashed line) models. The ‘peaks’ represent the residues that are found at a helix–helix
interface, and these are also listed above the peak maxima. For the trimer, when more
than one residue was found at an interface the peaks were slightly broadened.
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are not involved in oligomerization; see Fig. 2B) are oriented away
from the dimer and trimer interfaces. As mentioned above, these
residues are thought to participate in the binding of the BPV E5
protein [19] and should therefore be accessible, which is indeed what
is observed in both models.
3.5. The juxtamembrane regions of PDGFβR regulate transmembrane
helix–helix interactions
The strong self-association of the TM domain is surprising given
the lack of evidence supporting oligomerization of the full-length
protein (in the absence of ligand or the E5 protein) or any biological
relevance of a trimeric state. This may suggest that regions outside of
the TM domain play a role in regulating the TM helix–helix
interactions. Indeed, mutations in the cytoplasmic JM region of
PDGFβR and the related c-Kit receptor have been shown to lead to
ligand-independent activation [25,27,54], while the extra-cellular JM
domain of the Erythropoietin receptor (EpoR) is known to have a
controlling role in receptor function [55]. To investigate a role for the
PDGFβR JM regions in regulating TM domain oligomerization, we
expressed (in E. coli) and puriﬁed a truncated receptor containing the
TM domain, 40 residues of the N-terminal JM region, and the C-
terminal JM region previously investigated by Irusta et al. [26]. The
resulting protein was 105 residues in length, and contained residues
V460–P564. The oligomeric state of this construct was assessed by
SDS-PAGE (Fig. 8A, lane i) and immunoblotting to a His6 Tag
incorporated on the C-terminus. Two bands are observed on the
blot, corresponding to the molecular weights of monomer and dimer
(m and d, respectively). The dimeric state was further stabilized by
the addition of the crosslinking reagent Bis [sulfosuccinimidyl]
suberate (or BS3) to protein solubilized in 0.1% n-Dodecyl-β-D-
Maltoside (DDM) prior to analysis by SDS-PAGE, as shown in
Fig. 8A, lane ii. In comparison to the TM domain in isolation, the
longer protein contains a larger population of monomers in the
presence of SDS. However, a signiﬁcant amount of SDS-stable dimer
can be detected and this is increased when the dimer is stabilized ﬁrst
by crosslinking in the less-denaturing DDM detergent. QuantiﬁcationFig. 8. PDGFβR juxtamembrane (JM) regions control TM domain association. (A) SDS-
PAGE analysis of a puriﬁed, truncated PDGFβR protein containing the wt TM domain
and C- and N-terminal JM regions (residues V460 to P564). Samples were analyzed both
without (lane i) and with (lane ii) addition of the crosslinker BS3. A construct con-
taining an activating point mutation in the C-terminal JM region (V536A) was also
puriﬁed and analyzed using SDS-PAGE, again in the absence (lane iii) and presence
(lane iv) of BS3. Molecular weight markers are included in the far left lane, and the
oligomeric state is indicated on the right (m=monomer, d=dimer). Quantiﬁcation of
the resulting bands (see Materials and methods) yielded values of 4.8 and 6.5% dimer in
the absence of crosslinker for wt and V536A mutant, respectively, and 21.9 and 23.7%
dimer in the presence of crosslinker. (B) Circular dichroism spectra of puriﬁed wild-
type (solid line) and V536A mutant (dotted line) proteins in buffer containing 0.1%
dodecyl maltoside (DDM). The resulting spectra were analyzed for secondary structure
content using the CDSSTR software, and both analyses produced α-helical content of
15%.of the relative amounts of monomer and dimer (see Materials and
methods) resulted in values of 4.8% dimer in the absence of
crosslinker, and 21.97% dimer in the presence of crosslinker. This
∼4-fold increase in the percentage dimer upon addition of crosslinker
suggests that the dimeric state is stabilized by crosslinking. Evenmore
interesting is the fact that, apart from the dimer band, we saw no
evidence for any higher molecular weight species in any of the
Western blots. The trimer species which was identiﬁed (together
with the dimer) in the SDS-PAGE and AUC analyses of the TM domain
in isolation has been eliminated in the presence of the C- and N-
terminal JM domains, leaving only the more biologically-relevant
dimer species.
3.6. An activating point mutation in the cytoplasmic JM region does not
affect oligomerization or folding
The results presented above suggest that the JM regions of PDGFβR
can modify the oligomerization behavior of the TM domain. A
previous study of the cytoplasmic JM domain of the PDGFβR identiﬁed
a single point mutation (V536A) that lead to constitutive receptor
activation [25]. To investigate whether this mutation results in
changes to the oligomeric state, site-directed mutagenesis was used
to introduce the analogous V536A mutation into our truncated
receptor followed by analysis using SDS-PAGE (as above). The results
are shown in Fig. 8A (lanes iii and iv), and interestingly no changes in
the relative proportion of monomer or dimer are observed for the
mutant, in either the absence or presence of the BS3 crosslinker.
Quantiﬁcation of the relative amounts of monomer and dimer for the
V536A mutant resulted in values of 6.5% dimer in the absence of
crosslinker, and 23.7% dimer in the presence of crosslinker. These
values are very similar to those obtained for the wt sequence (above).
Additionally, circular dichroism (CD) was used to determine the
secondary structure content of both the wt and mutant constructs,
thus highlighting any differences in protein fold. The resulting spectra
of both proteins (Fig. 8B) are essentially identical. The CDSSTR [36]
programwas used to ﬁt the CD data and calculate secondary structure
content, and both wild-type and mutant spectra yielded α-helical
content of 15%. Comparison of this value to that predicted from the
protein sequences (using the program PROFsec on the PredictProtein
[37] server) produced very close agreement, with a predicted helical
content for both proteins of 14.11%. Thermal stability of the protein
fold was also assessed by CD measurements between 5 and 95 °C
using a Peltier temperature control unit, and again no difference
between the wt and mutant were observed (data not shown).
4. Discussion
We have carried out the ﬁrst detailed investigation of the TM
domain from PDGFβR, a key growth factor RTK that has roles in many
cellular functions. Appreciation of the importance of TM domains in
mediating protein–protein interactions in the membrane has in-
creased markedly in recent years (for review, see Ref. [56]), with the
TM domains of a number of growth factor receptors reported to play
key roles in receptor dimerization and subsequent activation of
downstream signalling cascades [2–6]. Evidence that the PDGFβR TM
domain is involved in receptor activation comes from studies of the
BPV E5 protein, where constitutive receptor signalling is mediated by
E5 interaction with the TM domain; however, to-date no biophysical
investigations have focussed speciﬁcally on this region. Our results
demonstrate that the PDGFβR TM domain has a very strong
propensity to form oligomers both in a natural membrane environ-
ment and in detergent micelles (giving dissociation constants for
homo-oligomerization in the nM range). This is contrary to the
oligomerization behavior reported for other RTK TM domains such as
the ﬁbroblast and epidermal growth factor receptors (FGFR3 and the
ErbB family), where dimerization is signiﬁcantly weaker than that for
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this receptor sub-type.
The presence of a trimeric species in both SDS-PAGE and AUC
analyses was unexpected, as this type of association of PDGFβR has
not been observed in a biological context. However, it is not without
precedent as Stanley and Fleming observed trimeric TM domains
from several members of the ErbB family of receptors using these
methods [51]. In the case of the ErbB TM domains, chemical cross-
linking was required to visualize the dimeric and trimeric states
on gels, and the observation of TM domain trimers using AUC was
dependent on the detergent concentration. It was therefore
hypothesized that high peptide-to-micelle ratios may be causing
non-preferential association as moremonomers are forced to occupy
individual micelles. Conversely, the data presented here, in partic-
ular the data shown in Fig. 3B, seem to suggest that the self-
association of the PDGFβR TM domain favors dimer and trimer
formation. Over a 10-fold change in peptide concentration (15–
150 µM) we detect monomer, dimer and trimer species; the only
other species observed is tetramer (or dimer of dimers) at the
highest concentrations. The trimer is the most prominent band
detected at all concentrations. It is worth noting that the trimer state
is only observed here for a short peptide in vitro (not for the longer
expressed protein in vivo), and therefore this trimer species may
result from an antiparallel arrangement of the TM domains that
would not be possible in native membranes in vivo. So while the
trimeric state of the TM domain may not be the biologically-relevant
form, it provides insight into the potentially large contribution of the
TM domain to ligand-independent protein self-association, perhaps
helping to stabilize pre-formed, inactive receptor dimers.
Molecular modelling and mutagenesis in this study support the
model that both the PDGFβR TM domain dimer and trimer are
stabilized by a very similar, leucine-zipper-like motif with key
residues located at the a and d positions of a heptad repeat. The
presence of leucine-zippers in transmembrane regions has been
explored in the literature [52,57]; and has been identiﬁed in other
RTK's, including ErbB2 [58,59] and DDR1 [60]. Interestingly, replace-
ment of the PDGFβR TM domain with that of the ErbB2 TM domain
from rat (also called the Neu proto-oncogene) resulted in a small
amount of ligand-independent signalling. This increased signiﬁcantly
upon replacement of the TM with the oncogenic form of Neu
(containing a single Val to Glu point mutation in the TM domain),
which is known to activate full-length ErbB2 bymediating TM domain
dimerization [61]. From the sequence alignment of the two TM
domains carried out by Petti et al. [61], the valine/glutamic acid
residue would fall on the leucine-zipper interface identiﬁed here (at
position L509). The interfacial motif identiﬁed here can be used as a
guide for further in vivo investigations to probe TM mediated
association in the full-length receptor.
We also see that the residues in the PDGFβR TMdomain thought to
bind to the E5 oncoprotein lie outside of both the predicted dimer and
trimer interfaces, which is consistent with the current model that
these residues are accessible for binding of E5 to a pre-formed (and
inactive) PDGFβR dimer. E5 binding may then trigger a conforma-
tional change in the receptor, causing it to adopt its active
conformation. This feasibly could occur through rotation of the helical
dimer from one interface to another, causing a more substantial
rearrangement of the soluble signalling domains in the full-length
receptor; however, any further speculation on the molecular
mechanism by which E5 causes PDGFβR activation is beyond the
scope of this work.
Although TM domain dimers and trimers are both observed in this
study, the trimeric form has not been observed for the full-length
receptor and is therefore not likely to be the most biologically-
relevant form. Indeed, by expressing a severely truncated (105 amino
acid) receptor containing the TM and C- and N-terminal juxtamem-
brane domains, we observed that the trimeric species is eliminatedentirely and only the dimer is formed. Therefore, the JM regions are
clearly involved in regulating the strong TM domain interactions and
guiding formation of the native oligomeric state. The observation of a
dimer species also suggests that ligand-independent, pre-formed
dimers may exist in vivo for the PDGFβR. The existence of unliganded
dimers has been reported for a number of other RTKs such as EGFR
[62], ErbB [6], EpoR [63], and a variety of other receptors (for an
excellent review see ref. [2]).
Mutagenesis of the truncated receptor at position 536 (V536A),
which produced constitutive activation of the PDGFβR in vivo in a
previous study [25], shows no change in the propensity to form
dimers nor does it show any change in the fold (as evaluated from CD
data). This is surprising in that this mutant in vivo produced levels of
Ba/F3 cell survival and proliferation comparable to those observed for
ligand-activated PDGFβR [25]. One explanation for this result could be
that the V536A mutation leads to PDGFβR activation via changes in
inter- or intramolecular protein–protein interactions, and not changes
in oligomeric state or secondary structure. The intra-cellular JM
domain of the closely-related c-Kit receptor has been shown to have
an auto-inhibitory function by inserting into the kinase-active site and
preventing formation of the active conformation [64]. Similarly, the
V536A mutation in PDGFβR may destabilize intramolecular auto-
inhibitory interactions of the JM domain, leading to the observed
constitutive receptor activation [25]. Although these data from the
literature suggest a more critical role for the intra-cellular JM domain
it is not clear from our results whether one or both JM regions are
exerting control over the observed oligomerization behavior.
Attempts to further pinpoint the required residues by expression of
shorter constructs resulted in poor expression levels; thus the precise
contribution of each JM domain remains unknown. Furthermore, it
will be of interest to investigate the mutations presented here in the
context of the full-length receptor.
In summary, we have used a wide variety of independent
biochemical and biophysical methods to provide the ﬁrst detailed
investigation of the role of the TM domain of PDGFβR in receptor
dimerization, and ﬁnd that it has key features in commonwith several
other RTKs. These features include signiﬁcant TM helix–helix
interactions (although in this case they are notably stronger) and
oligomerization via a leucine-zipper-like packing motif. The JM
domains modulate TM interactions and select for a single (dimeric)
oligomeric state in addition to monomer. However it is still to be
determined whether these pre-formed oligomers adopt the active or
inactive conformation. The C-terminal JM domain also appears to
regulate receptor activation via intra- or intermolecular protein
interactions, and not changes in fold or assembly.Acknowledgements
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